| 89.39 6.74 (8.15%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 120.3 | 1-year : | 140.51 |
| Resists | First : | 102.99 | Second : | 120.3 |
| Pivot price | 76.1 |
|||
| Supports | First : | 65.11 |
Second : | 41.7 |
| MAs | MA(5) : | 85.47 |
MA(20) : | 72.59 |
| MA(100) : | 45.67 |
MA(250) : | 34.77 |
|
| MACD | MACD : | 10.1 |
Signal : | 9.5 |
| %K %D | K(14,3) : | 55.6 |
D(3) : | 55.6  |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 102.99 | Low : | 12.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GRAL ] has closed below upper band by 13.6%. Bollinger Bands are 147.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 92.88 - 93.23 | 93.23 - 93.64 |
| Low: | 82.81 - 83.17 | 83.17 - 83.57 |
| Close: | 88.69 - 89.29 | 89.29 - 89.99 |
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Sat, 25 Oct 2025
GRAIL (GRAL): Evaluating Valuation After Key Study Results and Samsung Partnership Propel Global Growth Prospects - simplywall.st
Sat, 25 Oct 2025
Grail’s Stock Surges After Samsung Collaboration in Asia - timothysykes.com
Wed, 22 Oct 2025
GRAIL, Inc. (GRAL): A Bull Case Theory - Yahoo Finance
Tue, 21 Oct 2025
GRAIL Inc (GRAL) Gets a Buy from Canaccord Genuity - The Globe and Mail
Tue, 21 Oct 2025
GRAIL, Inc. (GRAL) Stock Analysis: A Diagnostic Pioneer with a 91.85 USD Peak Amidst a Potential -38.49% Downside - DirectorsTalk Interviews
Mon, 20 Oct 2025
Grail Inc. Early Cancer Detection News Boosts Healthcare Tech ETF HTEC - ETF Trends
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 36 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 68.4 (%) |
| Shares Short | 4,990 (K) |
| Shares Short P.Month | 4,840 (K) |
| EPS | -11.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 64.2 |
| Profit Margin | 0 % |
| Operating Margin | -368.2 % |
| Return on Assets (ttm) | -11.9 % |
| Return on Equity (ttm) | -17.7 % |
| Qtrly Rev. Growth | 11.1 % |
| Gross Profit (p.s.) | -2.11 |
| Sales Per Share | 3.72 |
| EBITDA (p.s.) | -11.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -370 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -7.64 |
| PEG Ratio | 0 |
| Price to Book value | 1.39 |
| Price to Sales | 23.99 |
| Price to Cash Flow | -8.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|